Bragar Eagel & Squire, P.C. reminds Zoetis, Inc. investors that the deadline to seek lead plaintiff appointment in a securities class action is July 27, 2026. The lawsuit, filed in the United States District Court for the Southern District of New York, covers purchasers of Zoetis securities between January 14, 2025 and May 6, 2026. The complaint alleges that the company failed to disclose weakening veterinarian prescription growth for its canine pain treatment Librela following FDA safety warnings, significant market share losses for Simparica Trio to a lower-priced competitor, and substantial market share erosion for dermatology products Apoquel and Cytopoint due to a newly launched rival treatment. Investors who suffered losses can contact the firm at investigations@bespc.com or (212) 355-4648.
Zoetis IncLawsuit alleges undisclosed FDA safety warnings for Librela, market share losses for Simparica Trio and dermatology products.